Delphinidin-3-sambubioside chloride

Research use only, not for human use.

Delphinidin-3-sambubioside chloride has antioxidant activity.

Delphinidin-3-sambubioside chloride has antioxidant activity.

Delphinidin-3-sambubioside chloride (50-200 μM, 30 min) inhibits LPS-induced iNOS expression in RAW264.7 cells.Delphinidin-3-sambubioside chloride (50-200 μM, 30 min) suppresses the phosphorylation of ERK1/2 and MEK1/2 in RAW264.7 cells.Delphinidin-3-sambubioside chloride (50-200 μM, 30 min) downregulates NF-κB signaling pathway in RAW264.7 cells.Delphinidin-3-sambubioside chloride (24 h) inhibits HL-60 cells proliferation by inducing apoptosis, with an IC50 of 75 μM.Delphinidin-3-sambubioside chloride (100-200 μg/mL, 24 h) decreases intracellular TG levels and lipid accumulation in oleic acid-treated HepG2 cells. Western Blot Analysis Cell Line:RAW264.7 cells Concentration:50, 100, 200 μM Incubation Time:30 min Result:Suppressed the degradation of IκB, and the phosphorylation of p65.

Delphinidin-3-sambubioside chloride (15 μmol/kg, i.p.) inhibits mouse paw edema induced by LPS.Delphinidin-3-sambubioside chloride (30 mg/kg body, oral gavage, daily for eight weeks) decreases lipid accumulation in HFD rats. Animal Model:Delphinidin-3-sambubioside chloride (15 μmol/kg, i.p.) .Dosage:15 μmol/kg Administration:Intraperitoneal injection (i.p.), for 4 days.Result:Reduced the LPS-induced paw thickness. Decreased the edema by 89.3%.Decreased the levels of LPS induced serum IL-6, MCP-1 and TNF-α.Animal Model:HFD-fed rats Dosage:30 mg/kg Administration:Oral gavage, daily for eight weeks.Result:Reduced the body weight gain, visceral fat, and abdominal fat and decreased hepatic lipid deposits.

——

Others

Other Targets

——

——

——

53158-73-9

633

C26H29O16Cl

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years